Veradermics Reports Sustained Hair Growth With VDPHL01 in 12-Month Trial Data

• Veradermics announced positive 12-month results from Study 302 Part B evaluating investigational oral minoxidil formulation VDPHL01 for male pattern hair loss.
• Twice-daily treatment deepened hair growth, while once-daily dosing maintained gains; patient reports and investigator assessments supported improved hair coverage.
• Treatment remained generally well tolerated, with no new safety signals or adverse-event-related study discontinuations during the additional six months.
• The findings support potential FDA approval as the first non-hormonal oral treatment for male pattern hair loss.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veradermics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611090700BIZWIRE_USPR_____20261109_BW139498) on November 09, 2026, and is solely responsible for the information contained therein.